RPL6

Across TCGA pan-cancer cohorts, RPL6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RPL6 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RPL6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL6 expression acts as an unfavorable survival marker, although some lineages such as COAD and LSCC show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where RPL6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.226	0.450	.005	25	view →
COAD	DFS	Median	III,IV	1.000	0.895	.039	12	view →
CCRCC	DFS	Tertile	III,IV	0.356	0.668	.021	9	view →
LSCC	OS	Median	II,III,IV	0.916	0.650	.002	8	view →
LUAD	DFS	Tertile	All	0.778	0.439	.019	4	view →
GBM	DFS	Quartile	All	0.287	0.476	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RPL6–PDAC (DFS)

Open the PDAC breakdown →